Topical Diclofenac Unnecessary Post-Photorefractive Keratectomy

This article originally appeared here.
Share this content:
Topical Diclofenac Unnecessary Post-Photorefractive Keratectomy
Topical Diclofenac Unnecessary Post-Photorefractive Keratectomy

FRIDAY, Jan. 9, 2015 (HealthDay News) -- For patients undergoing photorefractive keratectomy surgery, the administration of postoperative topical diclofenac does not alleviate pain, but is effective for local signs such as eyelid edema, according to a study published in the December issue of Clinical & Experimental Ophthalmology.

Alireza Eslampoor, M.D., from the Tehran University of Medical Sciences in Iran, and colleagues conducted a prospective randomized trial involving 68 individuals undergoing bilateral photorefractive keratectomy for myopic correction with or without astigmatism. Participants received 100 mg of extended-release oral diclofenac twice before surgery. After surgery, patients were randomized into case (diclofenac 0.1 percent drop administered for three days postoperatively) and control (given artificial tears) groups.

The researchers observed no significant between-group difference in pain level at two days after surgery. Furthermore, neither photophobia nor functional activity differed between the groups. In the control group, eyelid edema and conjunctival injection levels were significantly higher (P < 0.001).

"Administration of topical diclofenac to a standardized postoperative pain regime did not alleviate post-photorefractive keratectomy pain, although it is effective in local signs like eyelid edema and conjunctival injection," the authors write. "It can be concluded that oral diclofenac is sufficient in the management of post-photorefractive keratectomy pain and addition of the topical diclofenac is unnecessary."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »